EP0848000A1 — Pharmaceutical pyridine derivatives, processes for preparing the same and intermediates therefor
Assigned to Tanabe Pharma Corp · Expires 1998-06-17 · 28y expired
What this patent protects
A pyridine derivative of the formula (I): wherein A is group of the following formulae: R 1 and R 2 are each H, or protected or unprotected OH, R 31 , R 41 and R 42 are protected or unprotected hydroxymethyl, R 32 is H, lower alkyl, or protected or unprotected hydroxymet…
USPTO Abstract
A pyridine derivative of the formula (I): wherein A is group of the following formulae: R 1 and R 2 are each H, or protected or unprotected OH, R 31 , R 41 and R 42 are protected or unprotected hydroxymethyl, R 32 is H, lower alkyl, or protected or unprotected hydroxymethyl, R 33 is substituted or unsubstituted lower alkyl, and the dotted line means the presence or absence of a double bond' R 5 and R 6 are H, or protected or unprotected amino, or both combine together with the adjacent nitrogen to form substituted or unsubstituted heterocycle, or a pharmaceutically acceptable salt thereof, show excellent bronchoconstriction inhibitory activity and/or anti-inflammatory activity of airways, and are , useful in the prophylaxis or treatment of asthma.
Drugs covered by this patent
- Talzenna (Talazoparib Tosylate) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.